Skip to main content
. 2022 Aug 1;37(8):1602–1607. doi: 10.1038/s41433-022-02172-6

Table 2.

Distribution of VDR genotypes and gene variant alleles in KC patients versus control group.

KC patients (n = 177) n (%) Control (n = 85) n (%) Relative risk of KC
OR 95% CI P value
Taq I TT 37 (20.9%) 32 (37.6%) 1 - - R
Tt 80 (45.2%) 38 (44.7%) 1.820 0.988 3.353 0.054
tt 60 (33.9%) 15 (17.6%) 3.459 1.654 7.233 0.001
Tt + tt 140 (79.1%) 53 (62.4%) 2.284 1.293 4.035 0.004
T 154 (43.5%) 102 (60.0%) 1.948 1.343 2.825 <0.001
t 200 (56.5%) 68 (40.0%)
Apa I AA 64 (36.2%) 26 (30.6%) 1 - - R
Aa 85 (48.0%) 42 (49.4%) 0.822 0.457 1.478 0.513
aa 28 (15.8%) 17 (20.0%) 0.669 0.314 1.424 0.297
Aa + aa 113 (63.8%) 59 (69.4%) 0.778 0.447 1.354 0.374
A 213 (60.2%) 94 (55.3%) 0.818 0.565 1.185 0.289
a 141 (39.8%) 76 (44.7%)
Bsm I BB 61 (34.5%) 23 (27.1%) 1 - - R
Bb 75 (42.4%) 42 (49.4%) 0.673 0.365 1.239 0.204
bb 41 (23.1%) 20 (23.5%) 0.773 0.376 1.585 0.482
BB + bb 116 (65.5%) 62 (72.9%) 0.705 0.398 1.247 0.230
B 197 (55.6%) 88 (51.8%) 0.855 0.592 1.234 0.403
b 157 (44.4%) 82 (48.2%)

The bold numbers refer to the statistically significant values.

VDR vitamin D receptors, KC keratoconus, OR odds ratio, CI Confidence interval, R reference.